Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric heart failure study of LCZ696 versus enalapril
2015-004207-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan and enalapril in heart failure (HF) (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of LCZ696. Started Oct 2016; status: completed.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2015-004207-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004207-22.